Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
  Pharmaceutical Technology Europe E-Alert
 
19 August 2011

IN THIS ISSUE
Improper payments
Venture-capital funding
China GMP
TB battle

Pfizer discloses potentially improper payments
In its latest filing with the Securities and Exchange Commission (SEC), Pfizer indicated that it has voluntarily provided information concerning potentially improper payments made by Pfizer and Wyeth in connection with sales activities that took place outside of the US. More...
 
Murky picture for life science financing in second quarter
The second quarter of 2011 presented a mixed picture of financing for the life-science sector; although venture-capital funding for the sector as a whole showed strong improvement, biotechnology investing dropped in terms of overall dollars invested and number of deals. More...
 
China's SFDA following through on GMP efforts
Following the revision of China¹s State Food and Drug Administration (SFDA) last year, which became effective in March, the agency has been making other improvements to enhance the quality of its pharmaceutical manufacturing industry. More...
 
Bayer joins TB battle
Bayer Healthcare has pledged its support to a Tuberculosis (TB) partnership by providing 620000 tablets of the antibiotic moxifloxacin to the WHO, which will make the tablets available to China’s national TB programme. More...
 
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
 

Latest blog posts
An upward trajectory for new drug approvals
QbD In Theory And Practice
Never mind the Botox
More blog posts

Latest articles
Croatia, pharma and corruption
Making a mark in emerging markets
The importance of filter testing
More latest articles

Upcoming events
Biobanking Global Summit (6–7 September | UK)
European Chemicals Policy — REACH (7–8 September | Spain)
Impurities (14–15 September | Czech Republic)
More events

Product/Service Profiles
Rapid Micro Biosystems

The Growth Direct™ System is purpose built for microbial quality control in pharmaceutical manufacturing, detecting contamination earlier and automating the analysis of growing colonies. The device is non-destructive and easy to validate.
Read more


Live Webcast

Preventing Costly Out-of-Specification Investigations
Tues, 20 Sept 2011, 11:00 EST, 4:00 PM BST
Join Dr. Charles Ray, former Associate Director of Analytical R&D at Bristol-Myers Squibb Co. and he will show you how to tackle 50% of the errors that cause Out-of-Specification results by streamlining sample/standards preparation. More information...


Event profiles

Extractables & Leachables for Pharmaceutical Products
27-28 September 2011
Dublin, Ireland
Extractables and leachables assessment of all materials - especially from elastomeric and plastic components - forms an integral part of the submission for approval of a new drug system or medical device.Read more

 
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA borrow from EMA's pathway?
Borrow heavily from EMA's pathway program? 45%
 
Borrow lightly from EMA's pathway program? 26%
     
Create entirely its own pathway program? 26%

This week we would like to know...

What is your company's main driver for outsourcing biologics?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail
at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH, UK.